Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CEST
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH -0.37% 65.12 Delayed Quote.-9.16%
EXPRESS SCRIPTS HOLDING CO -0.37% 73.49 Delayed Quote.-1.54%
RITE AID CORPORATION -1.25% 1.58 Delayed Quote.-18.78%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
04/20CVS HEALTH CORPORATION : To Hold First Quarter 2018 Conference Call
PR
04/20CVS PHARMACY : Offering Hepatitis A Vaccine to Kentuckians Following an Increase..
PR
04/20CVS HEALTH : Ex-dividend day for
FA
04/19CVS HEALTH : Expands Safe Drug Disposal at CVS Pharmacy Locations in Ohio to Hel..
PR
04/19CVS PHARMACY : Launches First Campaign Featuring Unaltered Beauty Imagery
PR
04/19CVS HEALTH : EX-Dividend Schedule: CVS Health Has a Dividend Yield of 3.03%; Wil..
AC
04/18CVS HEALTH : Phoenix VA Health Care System, TriWest and CVS Health Mark First An..
PR
04/18CVS HEALTH : Names Marc-David Munk, MD, MPH, MHCM, as Chief Medical Officer of M..
AQ
04/17UnitedHealth earnings ease investor worries over flu season, stock up
RE
04/17CVS HEALTH : Today’s Research Reports on Trending Tickers: CVS Health and Centen..
AC
More news
News from SeekingAlpha
04/21THE PASSIVE DGI CORE PORTFOLIO : Income, Safety, And Growth 
04/20Vilas Fund, LP Q1 '18 Letter To Partners - #28 Since Inception, Long Pharma 
04/1910 Dividend Growth Stocks For April 2018 
04/19Jelly Beans, Group Think, And Greenblatt's Magic Formula 
04/193 Cheap Dividend Stocks To Consider 
Financials ($)
Sales 2018 189 B
EBIT 2018 10 003 M
Net income 2018 5 761 M
Debt 2018 20 873 M
Yield 2018 3,31%
P/E ratio 2018 11,98
P/E ratio 2019 10,66
EV / Sales 2018 0,46x
EV / Sales 2019 0,43x
Capitalization 66 066 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 87,9 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-9.16%66 066
WALGREENS BOOTS ALLIANCE-10.11%63 387
EXPRESS SCRIPTS HOLDING CO-1.54%41 267
MCKESSON CORPORATION-5.67%30 177
AMERISOURCEBERGEN-0.14%19 742
CARDINAL HEALTH1.70%19 534